Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/289040
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Computational Biology Dynamics of Mps1 Kinase Molecular Interactions with Isoflavones Reveals a Chemical Scaffold with Potential to Develop New Therapeutics for the Treatment of Cancer |
Autor: | Pugh, Lauren; Pancholi, Alisha; Purat, Priscila Celeste; Agudo-Álvarez, Sandra; Benito-Arenas, Raúl; Bastida, Agatha CSIC ORCID ; Bolanos-Garcia, Victor M. | Palabras clave: | Mps1 Cancer poor prognosis tumours flavonoid-like compounds bioinformatics molecular docking |
Fecha de publicación: | 2022 | Editor: | Molecular Diversity Preservation International | Citación: | International Journal of Molecular Sciences 23 (2022) | Resumen: | The protein kinase Mps1 (monopolar spindle 1) is an important regulator of the Spindle Assembly Checkpoint (SAC), the evolutionary conserved checkpoint system of higher organisms that monitors the proper bipolar attachment of all chromosomes to the mitotic spindle during cell division. Defects in the catalytic activity and the transcription regulation of Mps1 are associated with genome instability, aneuploidy, and cancer. Moreover, multiple Mps1 missense and frameshift mutations have been reported in a wide range of types of cancer of different tissue origin. Due to these features, Mps1 arises as one promising drug target for cancer therapy. In this contribution, we developed a computational biology approach to study the dynamics of human Mps1 kinase interaction with isoflavones, a class of natural flavonoids, and compared their predicted mode of binding with that observed in the crystal structure of Mps1 in complex with reversine, a small-sized inhibitor of Mps1 and Aurora B kinases. We concluded that isoflavones define a chemical scaffold that can be used to develop new Mps1 inhibitors for the treatment of cancer associated with Mps1 amplification and aberrant chromosome segregation. In a broader context, the present report illustrates how modern chemoinformatics approaches can accelerate drug development in oncology. | Versión del editor: | http://dx.doi.org/10.3390/ijms232214228 | URI: | http://hdl.handle.net/10261/289040 | DOI: | 10.3390/ijms232214228 | Identificadores: | doi: 10.3390/ijms232214228 issn: 1422-0067 |
Aparece en las colecciones: | (IQOG) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
ijms-23-14228.pdf | 4,9 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
1
checked on 20-abr-2024
WEB OF SCIENCETM
Citations
1
checked on 23-feb-2024
Page view(s)
25
checked on 24-abr-2024
Download(s)
30
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons